Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 11/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | CCR3 | P51677 | 4/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.40 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.40 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25920183 | 0.86 | L3MBTL3 (0.43) | L3MBTL3L3MBTL1KMT2A | |
| SCHEMBL30014881 | 0.83 | NPSR1 (0.51) | KMT2A | |
| SCHEMBL31161778 | 0.82 | MEN1 (0.45) | L3MBTL3L3MBTL1LRRK2HDAC4MEN1 | |
| SCHEMBL31161491 | 0.82 | MEN1 (0.45) | L3MBTL3L3MBTL1LRRK2HDAC4MEN1 | |
| SCHEMBL31255589 | 0.81 | LRRK2 (0.42) | L3MBTL3L3MBTL1LRRK2CCR3 | |
| Trifluoroacetic Acid SCHEMBL31161289 | 0.81 | LRRK2 (0.43) | L3MBTL3L3MBTL1LRRK2CCR3MBTD1 | |
| SCHEMBL26097569 | 0.81 | LRRK2 (0.40) | L3MBTL3L3MBTL1LRRK2MEN1KMT2A | |
| SCHEMBL30392231 | 0.81 | LRRK2 (0.40) | L3MBTL3L3MBTL1LRRK2MEN1KMT2A | |
| SCHEMBL29201743 | 0.79 | MGLL (0.42) | LRRK2MEN1KMT2A | |
| SCHEMBL30015013 | 0.79 | TSHR (0.43) | CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | L3MBTL3 3485/4885L3MBTL1 2460/4885LRRK2 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.